Treatment Patterns and Survival Outcomes Among Patients With Hepatocellular Carcinoma

What are the current treatment patterns, sequencing, and survival outcomes among patients receiving systemic therapy for hepatocellular carcinoma (HCC)?In this cohort study of 4198 patients treated with systemic therapy for HCC between 2011 and 2023, atezolizumab-bevacizumab and durvalumab-tremelimumab replaced sorafenib as the most common first-line therapy over time; only 20% of patients received second-line therapy. Median overall survival was 8.1 months and was not significantly associated with first-line systemic therapy type.These results suggest that the HCC treatment landscape has evolved considerably during the past decade, but more research is needed to determine optimal treatment sequencing.

Corresponding Author: Kelsey S. Lau-Min, MD, MSCE, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, 55 Fruit St, Yawkey 7E, Boston, MA 02114 (klau-min@mgh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.